• Antonio Hormigo Pozo, Desireé Torres Ortega, Antonio J García Ruiz, José Escribano Serrano, María Escribano Cobalea, and Nuria García-Agua Soler.
• Unidad de Gestión Clínica San Andres-Torcal Clinical, Distrito Málaga-Guadalhorce, Málaga, Spain.
• Aten Primaria. 2024 Feb 1; 56 (2): 102807102807.

AimsThe aim of this study is to analyse the effect of pharmacological and non-pharmacological treatment on weight control in patients with diabetes and obesity.DesignEpidemiological, descriptive, cross-sectional study. SITE: Primary care. In 11 health centres in Málaga and Cádiz during April and October 2022.Participants281 patients over 18 years old with type 2 diabetes and obesity are included.Main MeasurementsSocio-demographics, clinical, treatment and lifestyle habits variables were obtained from medical records and personal interview. Descriptive statistics were obtained for continuous variables. Statistical tests were performed based on the nature of the variables.ResultsVariables like marital status, level of education and occupation, and smoking habit, shows differences regarding the sex (p<0.05). 82.3% of those who received education lost weight, compared to 67.5% of lost weight who received no health education (p=0.004). GLP1 and SGLT2 were more commonly prescribed for women (p=0.048), and SGLT2 more commonly prescribed for men (p=0.047). Patients taking GLP1, SGLT2 or both, regardless of sex, weight loss during the study period was -3.1kg (SE: 0.60), while the loss of those who took other medications was -1.33kg (SE: 0.62). The mean difference was 1.75kg (p=0.046).ConclusionsIn terms of weight loss, obese diabetics who took GLP1, SGLT2 or both were 2.5 times more likely to lose weight than those who did not. Healthy lifestyle choices are key to weight loss in obese diabetic patients.Copyright © 2023 The Authors. Publicado por Elsevier España, S.L.U. All rights reserved.

28 keywords...

hide…